Ibandronate is a bisphosphonate used to treat osteoporosis in postmenopausal women.

Brand Names
Bondronat, Boniva, Bonviva, Iasibon
Generic Name
DrugBank Accession Number

Ibandronate, or BM 21.0955, is a third generation, nitrogen containing bisphosphonate similar to zoledronic acid, minodronic acid, and risedronic acid.1,2 It is used to prevent and treat postmenopausal osteoporosis.11,12 Ibandronate was first described in the literature in 1993 as a treatment for bone loss in dogs.2

Ibandronate was granted FDA approval on 16 May 2003.11

Small Molecule
Approved, Investigational
Average: 319.2289
Monoisotopic: 319.094975119
Chemical Formula
  • ácido ibandrónico
  • Ibandronic acid
External IDs
  • R484



For the treatment and prevention of osteoporosis in postmenopausal women.11,12

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more

Ibandronate is a nitrogen containing bisphosphonate used to treat and prevent osteoporosis in postmenopausal women.11,12 The therapeutic index is wide as overdoses are not especially toxic, and the duration of action is long as the half life can be up to 157 hours.11,12 Patients should be counselled regarding the risk of upper GI adverse reactions, hypocalcemia, musculoskeletal pain, osteonecrosis of the jaw, atypical fractures of the femur, and severe renal impairment.11,12

Mechanism of action

Bisphosphonates are taken into the bone where they bind to hydroxyapatite. Bone resorption by osteoclasts causes local acidification, releasing the bisphosphonate, which is taken into the osteoclast by fluid-phase endocytosis.5 Endocytic vesicles become acidified, releasing bisphosphonates into the cytosol of osteoclasts where they act.5

Osteoclasts mediate resorption of bone.6 When osteoclasts bind to bone they form podosomes, ring structures of F-actin.6 Disruption of the podosomes causes osteoclasts to detach from bones, preventing bone resorption.6

Nitrogen containing bisphosphonates such as ibandronate are known to induce apoptosis of hematopoietic tumor cells by inhibiting the components of the mevalonate pathway farnesyl diphosphate synthase, farnesyl diphosphate, and geranylgeranyl diphosphate.7,3 These components are essential for post-translational prenylation of GTP-binding proteins like Rap1.7 The lack of prenylation of these proteins interferes with their function, and in the case of Rap1, leads to apoptosis.7 ibandronate also activated caspase-3 which contribute to apoptosis.4

AGeranylgeranyl pyrophosphate synthase
AFarnesyl pyrophosphate synthase

Oral ibandronate is 0.63% bioavailable.8 In a study of healthy males, a 10mg oral dose had a Tmax of 1.1±0.6h and a Cmax of 4.1±2.6ng/mL.10 The Tmax is approximately 1 hour, while Cmax varies depending on dose.10

A 2mg intravenous dose of ibandronate has an AUC of 316ng*h/mL, a 4mg intravenous dose of ibandronate has an AUC of 581ng*h/mL, and a 6mg intravenous dose of ibandronate has an AUC of 908ng*h/mL.9

Volume of distribution

The apparent terminal volume of distribution of ibandronate is 90-368L in headlthy subjects and 103L in postmenopausal women with osteopenia.8,11,12

Protein binding

Ibandronate's protein binding in serum varies from 85.7-99.5% over a concentration of 0.5-10ng/mL,11 but is generally 86% across a concentration range of 20-2000ng/mL.12


Ibanronate is not metabolized in humans.11,12

Route of elimination

Ibandronate is predominantly eliminated in the urine and the unabsorbed drug is eliminated unchanged in the feces.8,11,12


The half life of ibandronate in postmenopausal women ranges from 37-157 hours.11,12


The total clearance of ibandronate is 84-160mL/min.11,12

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more

Patients experiencing an overdose may present with hypocalcemia, hypophosphatemia, upset stomach, dyspepsia, esophagitis, and uclers.11,12 Oral overdose can be managed by giving patients milk or antacids to bind excess unabsorbed ibandronate.11 Overdoses can be managed by providing intravenous electrolytes and dialysis is not expected to remove excess drug from serum.11,12

Ibandronate Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available


Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
AceclofenacThe risk or severity of gastrointestinal bleeding can be increased when Aceclofenac is combined with Ibandronate.
AcemetacinThe risk or severity of gastrointestinal bleeding can be increased when Acemetacin is combined with Ibandronate.
Acetylsalicylic acidThe risk or severity of gastrointestinal bleeding can be increased when Acetylsalicylic acid is combined with Ibandronate.
AcipimoxThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ibandronate is combined with Acipimox.
AcrivastineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Acrivastine.
AcyclovirThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Acyclovir is combined with Ibandronate.
Adefovir dipivoxilThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Adefovir dipivoxil is combined with Ibandronate.
AdenosineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Adenosine.
AfliberceptThe risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Aflibercept is combined with Ibandronate.
AjmalineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Ajmaline.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
  • Take on an empty stomach.
  • Take with a full glass of water. Do not take this medication with other liquids.


Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Ibandronate sodiumJ12U072QL0138926-19-9VBDRTGFACFYFCT-UHFFFAOYSA-M
Product Images
International/Other Brands
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
BondenzaTablet, film coated150 mgOralRoche Registration Limited2016-09-072013-05-13EU flag
BondenzaInjection, solution3 mgIntravenousRoche Registration Limited2016-09-072013-05-13EU flag
BondenzaTablet, film coated150 mgOralRoche Registration Limited2016-09-072013-05-13EU flag
BondenzaInjection, solution3 mgIntravenousRoche Registration Limited2016-09-072013-05-13EU flag
BondronatInjection, solution, concentrate2 mgIntravenousAtnahs Pharma Netherlands B.V.2021-02-11Not applicableEU flag
BondronatInjection, solution, concentrate6 mgIntravenousAtnahs Pharma Netherlands B.V.2021-02-11Not applicableEU flag
BondronatTablet, film coated50 mgOralAtnahs Pharma Netherlands B.V.2021-02-11Not applicableEU flag
BondronatLiquid1 mg / mLIntravenousHoffmann La Roche2004-05-312006-05-17Canada flag
BondronatInjection, solution, concentrate6 mgIntravenousAtnahs Pharma Netherlands B.V.2021-02-11Not applicableEU flag
BondronatTablet, film coated50 mgOralAtnahs Pharma Netherlands B.V.2021-02-11Not applicableEU flag
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
EUTROBONSolution3.207 mgIntravenous2014-03-25Not applicable
FOSFONATTablet150.000 mgOralLaboratorios Liomont, S.A. de C.V.2013-05-17Not applicable
Ibandronate SodiumInjection, solution3 mg/3mLIntravenousMylan Institutional2014-09-02Not applicableUS flag
Ibandronate SodiumTablet150 mg/1OralActavis Pharma, Inc.2012-03-202018-06-30US flag
Ibandronate SodiumInjection, solution3 mg/3mLIntravenousSagent Pharmaceuticals2014-09-02Not applicableUS flag
Ibandronate sodiumTablet150 mg/1OralDr. Reddy's Laboratories Limited2012-06-21Not applicableUS flag
Ibandronate SodiumInjection, solution3 mg/3mLIntravenousTAGI Pharma, Inc.2022-06-30Not applicableUS flag
Ibandronate SodiumTablet, film coated150 mg/1OralMylan Pharmaceuticals2012-03-192015-06-30US flag
Ibandronate SodiumTablet, film coated150 mg/1OralMacleods Pharmaceuticals Limited2017-11-01Not applicableUS flag
Ibandronate SodiumTablet150 mg/1OralAlvogen Inc.2014-05-01Not applicableUS flag
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
ASCENDRA TRIO 500CA+1000D3Ibandronate (1 mg/mL) + Calcium carbonate (500 mg) + Cholecalciferol (1000 IU)Injection, solutionParenteral2019-04-01Not applicableGermany flag
IBAMIN D3 150 MG/2800 IU FİLM KAPLI TABLET, 3 ADETIbandronate sodium (168.78 mg) + Cholecalciferol (2800 IU)Tablet, coatedOralCELTİS İLAÇ SAN. VE TİC. A.Ş.2020-08-14Not applicableTurkey flag
IBAMIN D3 150 MG/2800 IU SAŞE ,3 SAŞEIbandronate sodium (168.78 mg) + Cholecalciferol (2800 IU)PowderOralCELTİS İLAÇ SAN. VE TİC. A.Ş.2020-08-14Not applicableTurkey flag
IBONE D 30000Ibandronate (150 mg) + Cholecalciferol (30000 IU)Tablet, coatedOral2018-01-29Not applicableColombia flag
IBONE D®Ibandronate sodium (150 mg) + Cholecalciferol (12000 IU)Tablet, coatedOralLABORATORIOS SYNTHESIS S.A.S.2013-04-18Not applicableColombia flag
SOLIDENATIbandronate sodium (168.75 mg) + Cholecalciferol (240.00 mg)TabletOralProductos Cientificos s.a. De c.v.2020-02-07Not applicable


ATC Codes
M05BA06 — Ibandronic acidM05BB09 — Ibandronic acid and colecalciferol
Drug Categories
Chemical TaxonomyProvided by Classyfire
This compound belongs to the class of organic compounds known as bisphosphonates. These are organic compounds containing two phosphonate groups linked together through a carbon atoms.
Organic compounds
Super Class
Organic acids and derivatives
Organic phosphonic acids and derivatives
Sub Class
Direct Parent
Alternative Parents
Organic phosphonic acids / 1,3-aminoalcohols / Trialkylamines / Organopnictogen compounds / Organophosphorus compounds / Organooxygen compounds / Organic oxides / Hydrocarbon derivatives
1,3-aminoalcohol / Aliphatic acyclic compound / Amine / Bisphosphonate / Hydrocarbon derivative / Organic nitrogen compound / Organic oxide / Organic oxygen compound / Organonitrogen compound / Organooxygen compound
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
Not Available
Affected organisms
  • Humans and other mammals

Chemical Identifiers

CAS number
InChI Key
{1-hydroxy-3-[methyl(pentyl)amino]-1-phosphonopropyl}phosphonic acid


Synthesis Reference

Revital Lifshitz-Liron, Thomas Bayer, Judith Aronhime, Michael Pinchasov, "Solid and crystalline ibandronate sodium and processes for preparation thereof." U.S. Patent US20070179119, issued August 02, 2007.

General References
  1. Cremers S, Drake MT, Ebetino FH, Bilezikian JP, Russell RGG: Pharmacology of bisphosphonates. Br J Clin Pharmacol. 2019 Jun;85(6):1052-1062. doi: 10.1111/bcp.13867. Epub 2019 Feb 28. [Article]
  2. Monier-Faugere MC, Friedler RM, Bauss F, Malluche HH: A new bisphosphonate, BM 21.0955, prevents bone loss associated with cessation of ovarian function in experimental dogs. J Bone Miner Res. 1993 Nov;8(11):1345-55. doi: 10.1002/jbmr.5650081109. [Article]
  3. Cao R, Chen CK, Guo RT, Wang AH, Oldfield E: Structures of a potent phenylalkyl bisphosphonate inhibitor bound to farnesyl and geranylgeranyl diphosphate synthases. Proteins. 2008 Nov 1;73(2):431-9. doi: 10.1002/prot.22066. [Article]
  4. Hiraga T, Williams PJ, Mundy GR, Yoneda T: The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases. Cancer Res. 2001 Jun 1;61(11):4418-24. [Article]
  5. Russell RG, Watts NB, Ebetino FH, Rogers MJ: Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int. 2008 Jun;19(6):733-59. doi: 10.1007/s00198-007-0540-8. [Article]
  6. Murakami H, Takahashi N, Tanaka S, Nakamura I, Udagawa N, Nakajo S, Nakaya K, Abe M, Yuda Y, Konno F, Barbier A, Suda T: Tiludronate inhibits protein tyrosine phosphatase activity in osteoclasts. Bone. 1997 May;20(5):399-404. [Article]
  7. Miwa A, Takezako N, Hayakawa H, Hayakawa M, Tominaga S, Yanagisawa K: YM-175 induces apoptosis of human native monocyte-lineage cells via inhibition of prenylation. Am J Hematol. 2012 Dec;87(12):1084-8. doi: 10.1002/ajh.23328. Epub 2012 Oct 9. [Article]
  8. Reginster JY, Neuprez A, Bruyere O: Ibandronate in profile: drug characteristics and clinical efficacy. Expert Opin Drug Metab Toxicol. 2008 Jul;4(7):941-51. doi: 10.1517/17425255.4.7.941. [Article]
  9. Croom KF, Scott LJ: Intravenous ibandronate: in the treatment of osteoporosis. Drugs. 2006;66(12):1593-601; discussion 1602-3. doi: 10.2165/00003495-200666120-00005. [Article]
  10. Barrett J, Worth E, Bauss F, Epstein S: Ibandronate: a clinical pharmacological and pharmacokinetic update. J Clin Pharmacol. 2004 Sep;44(9):951-65. doi: 10.1177/0091270004267594. [Article]
  11. FDA Approved Drug Products: Boniva Ibandronate Oral Tablets [Link]
  12. FDA Approved Drug Products: Boniva Ibandronate Intravenous Injection [Link]
Human Metabolome Database
PubChem Compound
PubChem Substance
Therapeutic Targets Database
PDBe Ligand
RxList Drug Page
Drugs.com Drug Page
PDB Entries
2f94 / 4umj / 6o9p / 6r4v
FDA label
Download (296 KB)
Download (16 KB)

Clinical Trials

Clinical Trials
4CompletedPreventionOsteopenia (Disorder) / Osteoporosis / Rheumatoid Arthritis1
4CompletedTreatmentCirrhosis of the Liver1
4CompletedTreatmentPain; Bone Neoplasms; Neoplasm Metastasis2
4CompletedTreatmentPostmenopausal Osteopenia1
4CompletedTreatmentPostmenopausal Osteoporosis16
4CompletedTreatmentSystemic Lupus Erythematosus1
4TerminatedTreatmentLung Cancer1
4WithdrawnTreatmentHuman Immunodeficiency Virus (HIV) Infections1


  • Hoffmann la roche inc
  • Diversified Healthcare Services Inc.
  • F Hoffmann La Roche Ltd.
  • F Hoffmann-La Roche Ltd.
  • Physicians Total Care Inc.
  • Vetter Pharma Fertigung GmbH and Co. KG
Dosage Forms
Tablet, coatedOral168.8 mg
Injection, solutionIntravenous; Parenteral3 MG
Injection, solution, concentrateIntravenous3 MG
Injection, solution, concentrateIntravenous6 MG
Solution, concentrateIntravenous2 MG
Injection, solution3 MG
Injection, solution, concentrateIntravenous; Parenteral2 MG
Injection, solution, concentrateIntravenous; Parenteral6 MG
Tablet, coatedOral168.795 mg
Injection, solutionParenteral3 MG
Injection, solutionParenteral
Injection, solution, concentrateIntravenous3 mg/3ml
Capsule, liquid filledOral150 mg
Injection, solutionIntravenous
Injection, solutionIntravenous3 mg
InjectionIntravenous6 mg/6ml
Injection, solution, concentrateIntravenous2 mg/2ml
Injection, solution, concentrateIntravenous2 mg
Injection, solution, concentrateIntravenous6 mg/6ml
LiquidIntravenous1 mg / mL
SolutionParenteral2 MG
SolutionParenteral6 MG
SolutionParenteral6 MG/6ML
SolutionIntravenous6 mg
SolutionIntravenous3 mg
InjectionIntravenous1 MG/ML
Injection, solutionIntravenous3 mg/3mL
Tablet, film coatedOral150 mg/1
Tablet, film coatedOral2.5 mg/1
Injection, solutionIntravenous; Parenteral3 MG/3ML
TabletOral150 MG
Injection, solutionParenteral3 MG/3ML
Injection, solutionParenteral3 MG/ML
Tablet, film coatedOral168.75 mg
SolutionIntravenous3.207 mg
TabletOral150.000 mg
Injection, solution, concentrateIntravenous1 mg
PowderOral56.27 mg
Tablet, coatedOral
Solution, concentrateIntravenous6 mg
InjectionIntravenous3 mg/3mL
TabletOral150 mg/1
SolutionParenteral2 MG/2ML
SolutionParenteral4 MG
Injection, solutionParenteral
Injection, solution, concentrateIntravenous
Tablet, film coatedOral
Tablet, film coatedOral50 MG
SolutionIntravenous3.000 mg
Injection, solution
SolutionIntravenous6 mg/6ml
SolutionIntravenous3 mg/3ml
Tablet, film coatedOral150 mg
Solution1 ml/1ml
Tablet, coatedOral150 mg
Unit descriptionCostUnit
Boniva 3 mg/3ml Kit Box524.22USD box
Boniva 3 mg/3 ml syringe504.06USD syringe
Boniva 3 150 mg tablet Disp Pack388.93USD disp
Boniva 150 mg tablet124.66USD tablet
Boniva 2.5 mg tablet4.16USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patent NumberPediatric ExtensionApprovedExpires (estimated)Region
US4927814No1990-05-222012-03-17US flag
CA2346662No2006-05-092019-10-01Canada flag
US7192938Yes2007-03-202023-11-06US flag
US7718634Yes2010-05-182023-11-06US flag
US7410957No2008-08-122023-05-06US flag
US6294196No2001-09-252019-10-07US flag
US6143326No2000-11-072017-04-21US flag


Experimental Properties
melting point (°C)113-115ChemSpider
water solubilityFreely solubleFDA Label
Predicted Properties
Water Solubility13.4 mg/mLALOGPS
pKa (Strongest Acidic)0.66Chemaxon
pKa (Strongest Basic)9.93Chemaxon
Physiological Charge-2Chemaxon
Hydrogen Acceptor Count8Chemaxon
Hydrogen Donor Count5Chemaxon
Polar Surface Area138.53 Å2Chemaxon
Rotatable Bond Count9Chemaxon
Refractivity71.16 m3·mol-1Chemaxon
Polarizability29.06 Å3Chemaxon
Number of Rings0Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Human Intestinal Absorption-0.9664
Blood Brain Barrier-0.5229
Caco-2 permeable-0.6012
P-glycoprotein substrateSubstrate0.6888
P-glycoprotein inhibitor INon-inhibitor0.8195
P-glycoprotein inhibitor IINon-inhibitor0.9838
Renal organic cation transporterNon-inhibitor0.9092
CYP450 2C9 substrateNon-substrate0.8376
CYP450 2D6 substrateNon-substrate0.7863
CYP450 3A4 substrateNon-substrate0.5504
CYP450 1A2 substrateNon-inhibitor0.832
CYP450 2C9 inhibitorNon-inhibitor0.8159
CYP450 2D6 inhibitorNon-inhibitor0.8987
CYP450 2C19 inhibitorNon-inhibitor0.8045
CYP450 3A4 inhibitorNon-inhibitor0.8901
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9945
Ames testNon AMES toxic0.6527
BiodegradationNot ready biodegradable0.8346
Rat acute toxicity2.4278 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6061
hERG inhibition (predictor II)Non-inhibitor0.6622
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)


Mass Spec (NIST)
Not Available
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available


Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Small molecule
Pharmacological action
  1. Jahnke W, Henry C: An in vitro assay to measure targeted drug delivery to bone mineral. ChemMedChem. 2010 May 3;5(5):770-6. doi: 10.1002/cmdc.201000016. [Article]
  2. Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W, Mangood A, Russell RG, Ebetino FH: Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone. 2006 May;38(5):617-27. Epub 2005 Jul 20. [Article]
Pharmacological action
General Function
Metal ion binding
Specific Function
Catalyzes the trans-addition of the three molecules of IPP onto DMAPP to form geranylgeranyl pyrophosphate, an important precursor of carotenoids and geranylated proteins.
Gene Name
Uniprot ID
Uniprot Name
Geranylgeranyl pyrophosphate synthase
Molecular Weight
34870.625 Da
  1. Guo RT, Cao R, Liang PH, Ko TP, Chang TH, Hudock MP, Jeng WY, Chen CK, Zhang Y, Song Y, Kuo CJ, Yin F, Oldfield E, Wang AH: Bisphosphonates target multiple sites in both cis- and trans-prenyltransferases. Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10022-7. Epub 2007 May 29. [Article]
Pharmacological action
General Function
Poly(a) rna binding
Specific Function
Key enzyme in isoprenoid biosynthesis which catalyzes the formation of farnesyl diphosphate (FPP), a precursor for several classes of essential metabolites including sterols, dolichols, carotenoids...
Gene Name
Uniprot ID
Uniprot Name
Farnesyl pyrophosphate synthase
Molecular Weight
48275.03 Da
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [Article]
  2. Chapurlat RD, Delmas PD: Drug insight: Bisphosphonates for postmenopausal osteoporosis. Nat Clin Pract Endocrinol Metab. 2006 Apr;2(4):211-9; quiz following 238. [Article]
  3. Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ: Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther. 2001 Feb;296(2):235-42. [Article]
  4. Rondeau JM, Bitsch F, Bourgier E, Geiser M, Hemmig R, Kroemer M, Lehmann S, Ramage P, Rieffel S, Strauss A, Green JR, Jahnke W: Structural basis for the exceptional in vivo efficacy of bisphosphonate drugs. ChemMedChem. 2006 Feb;1(2):267-73. [Article]

Drug created at June 13, 2005 13:24 / Updated at April 07, 2023 13:28